Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. The Company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptor (CAR)-based therapy that is in Phase 2 clinical trials for patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma.

Employee Rating

3.4More
TypeSubsidiary
Parent CompanyGilead Sciences
HQSanta Monica, CA, US
Founded2009
Websitekitepharma.com
Cybersecurity ratingBMore
Kite Pharma was founded in 2009 and is headquartered in Santa Monica, CA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Kite Pharma

Christi Shaw

Christi Shaw

Chief Executive Officer
Brad Glover

Brad Glover

VP & Head of Strategy
Adrian Bot

Adrian Bot

VP of Scientific Affairs
Show more

Kite Pharma Office Locations

Kite Pharma has offices in Santa Monica, El Segundo, Emeryville, Frederick and in 4 other locations
Santa Monica, CA, US (HQ)
2400 Broadway
El Segundo, CA, US
2355 Utah Ave
Emeryville, CA, US
5858 Horton St #240
Frederick, MD, US
Bennett Creek Blvd
Oceanside, CA, US
4010 Ocean Ranch Blvd
Amsterdam, NL
408 Science Park
Show all (9)

Kite Pharma Financials and Metrics

Summary Metrics

Founding Date

2009

Total Funding

$85.3 m

Investors

In total, Kite Pharma had raised $85.3 m. Kite Pharma is a subsidiary of Gilead Sciences

Kite Pharma Revenue

Kite Pharma's revenue was reported to be $22.17 m in FY, 2016 which is a 28.5% increase from the previous period.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

17.3m22.2m

Revenue growth, %

28%

General and administrative expense

13.6m44.2m97.4m

R&D expense

23.1m76.4m197.9m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

2.9m4.4m5.1m5.1m4.8m7.3m9.8m10.1m

General and administrative expense

9.2m9.8m11.1m16.5m23.5m25.0m35.8m41.1m

R&D expense

9.3m16.6m21.7m34.4m47.4m57.3m65.9m70.9m

Operating expense total

18.4m26.4m32.9m50.9m70.9m82.3m101.7m112.0m
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

209.3m392.8m114.6m

Current Assets

368.4m631.1m427.4m

PP&E

2.1m30.1m44.4m

Goodwill

25.4m24.5m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

283.9m263.2m173.0m199.6m170.2m128.8m565.2m147.8m

Current Assets

435.0m403.3m381.5m592.5m541.6m491.1m819.2m798.3m

PP&E

4.3m11.3m20.3m40.5m42.5m43.5m46.2m49.7m

Goodwill

24.7m25.8m26.1m26.4m25.8m26.1m24.8m26.6m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(42.6m)(101.7m)(267.1m)

Depreciation and Amortization

261.6m4.6m10.6m

Accounts Payable

2.3m4.5m2.3m

Cash From Operating Activities

(17.1m)(16.1m)(168.9m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(15.1m)(36.0m)(63.4m)(43.9m)(108.2m)(182.1m)(90.4m)(200.2m)

Depreciation and Amortization

290.0k1.5m2.9m1.9m4.5m7.5m3.2m6.6m

Accounts Payable

5.6m2.1m2.6m(141.0k)(1.4m)3.0m2.3m2.0m

Cash From Operating Activities

53.1m24.4m6.9m(28.7m)(64.9m)(115.0m)(17.8m)(52.7m)
USDFY, 2014

Financial Leverage

1 x
Show all financial metrics

Kite Pharma Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Kite Pharma Online and Social Media Presence

Embed Graph

Kite Pharma Company Culture

  • Overall Culture

    D-

    56/100

  • CEO Rating

    D

    61/100

  • Compensation

    D

    55/100

  • Diversity

    F

    45/100

Learn more on Comparably

Kite Pharma News and Updates

Global Cell and Gene Therapy Drug Delivery Devices Market Report 2021 Featuring Major Players - Novartis, Kite Pharma, and Dendreon Pharmaceuticals

Dublin, March 26, 2021 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Drug Delivery Devices Market: Focus on Product Type, Commercialized Drug Delivery Devices, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMar…

Confirmed: Gilead to acquire Kite Pharma for $11.9bn

Shares in Kite Pharma, a US pharmaceuticals firm, have rocketed more than 16 per cent in pre-market trading after reports that it is being acquired. Gilead Sciences has confirmed it has offered $11.9bn (£9.2bn) for the company, in a deal first reported by the Wall Street Journal, $180 per share a…

Kite Pharma's ASCO ads aim to prep docs on CAR-T ahead of FDA approval

Drugmakers put up plenty of ads at ASCO, but only one campaign covered a class of meds that isn't even approved yet. That would be Kite Pharma's CAR-T cell therapy promos, designed to highlight the biotech's educational push for the immunotherapy.

Kite Pharma Frequently Asked Questions

  • When was Kite Pharma founded?

    Kite Pharma was founded in 2009.

  • Who are Kite Pharma key executives?

    Kite Pharma's key executives are Christi Shaw, Brad Glover and Adrian Bot.

  • How many employees does Kite Pharma have?

    Kite Pharma has 2,485 employees.

  • What is Kite Pharma revenue?

    Latest Kite Pharma annual revenue is $22.2 m.

  • What is Kite Pharma revenue per employee?

    Latest Kite Pharma revenue per employee is $8.9 k.

  • Who are Kite Pharma competitors?

    Competitors of Kite Pharma include G1 Therapeutics, Achilles Therapeutics and BioNTech.

  • Where is Kite Pharma headquarters?

    Kite Pharma headquarters is located at 2400 Broadway, Santa Monica.

  • Where are Kite Pharma offices?

    Kite Pharma has offices in Santa Monica, El Segundo, Emeryville, Frederick and in 4 other locations.

  • How many offices does Kite Pharma have?

    Kite Pharma has 9 offices.